Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFZS8A)

• Drug Name: CD38 and BCMA CAR-T Cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMFZS8A

Molecule-Related Drug Atlas

Drug(s) Targeting Cyclic ADP-ribose hydrolase 1 (CD38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daratumumab	DMKCIUZ	Multiple myeloma	2A83	Approved	[2]
Mezagitamab	DMWJXFO	Myasthenia gravis	8C6Y	Phase 2	[3]
4SCAR19 and 4SCAR38	DMZKFU7	B-cell lymphoma	2A86	Phase 1/2	[4]
ISB 1342	DMG107N	Multiple myeloma	2A83	Phase 1/2	[5]
Anti-CD38 CAR-T cells	DMTVXBY	Multiple myeloma	2A83	Phase 1/2	[6]
CD38 CAR T cells	DMPS3I6	Multiple myeloma	2A83	Phase 1/2	[7]
CD38 CAR-T Cell	DM0USBX	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[8]
SAR-650984	DMD20YH	Haematological malignancy	2B33.Y	Phase 1/2	[9]
MOR-202	DMR8AHJ	Multiple myeloma	2A83	Phase 1/2	[10]
Anti-CD38 CAR-T cells	DMTVXBY	Multiple myeloma	2A83	Phase 1/2	[11]

Drug(s) Targeting B-cell maturation protein (TNFRSF17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Idecabtagene vicleucel	DMP1QTS	Multiple myeloma	2A83	Approved	[12]
Belantamab mafodotin	DMBT3AI	Multiple myeloma	2A83	Approved	[13]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[14]
Teclistamab	DMGR8JI	Multiple myeloma	2A83	Approved	[15]
Ciltacabtagene autoleucel	DMU2J7Y	Multiple myeloma	2A83	Phase 3	[16]
Bb2121	DMB0UF9	Multiple myeloma	2A83	Phase 2	[17]
LCAR-B38M CAR-T Cell	DMQZJNA	Multiple myeloma	2A83	Phase 2	[18]
Descartes-08	DM63P1W	Multiple myeloma	2A83	Phase 2	[19]
Descartes-11	DM1UO4S	Multiple myeloma	2A83	Phase 2	[20]
CART-19/BCMA	DMVW1GY	Multiple myeloma	2A83	Phase 1/2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell maturation protein (TNFRSF17)	TTZ3P4W	TNR17_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
Cyclic ADP-ribose hydrolase 1 (CD38)	TTPURFN	CD38_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
• [2] Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
• [3] Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325.
• [4] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [5] Clinical pipeline report, company report or official report of Ichnos Sciences.
• [6] ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
• [7] ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
• [8] ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
• [9] Clinical pipeline report, company report or official report of Sanofi-Aventis.
• [10] Clinical pipeline report, company report or official report of MorphoSys.
• [11] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [14] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [15] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.
• [16] ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
• [19] ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
• [20] Clinical pipeline report, company report or official report of Cartesian Therapeutics.
• [21] ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT